Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Chidamide in CBF Leukemia
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC) or high-dose cytarabine plus chidamide.The safety and efficacy of chidamide is evaluated.
Key Details
Gender
All
Age Range
14 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
250
Start Date
2017-02-08
Completion Date
2027-12-30
Last Updated
2025-05-30
Healthy Volunteers
No
Conditions
Interventions
Cytarabine
Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
Chidamide
Chidamide at a dose of 20mg/d twice a week for 3 months.
Locations (1)
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China